---
document_datetime: 2025-11-23 08:02:24
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals.html
document_name: prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals.html
version: success
processing_time: 0.4466341
conversion_datetime: 2025-12-26 11:45:33.837103
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Prepandemic Influenza Vaccine (H5N1) (Split Virion, Inactivated, Adjuvanted) GlaxoSmithKline Biologicals

[RSS](/en/individual-human-medicine.xml/66254)

##### Withdrawn

This medicine's authorisation has been withdrawn

prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted)

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On the 26 September 2008 the European Commission issued a marketing authorisation valid throughout the European Union for the medicinal product Prepandemic influenza vaccine (H5N1) GlaxoSmithKline Biologicals, prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) A/VietNam/1194/2004 NIBRG-14, which had been approved as for prophylaxis of influenza in an officially declared pandemic situation.

The marketing authorisation holder (MAH) responsible for Prepandemic influenza vaccine (H5N1) GlaxoSmithKline Biologicals was GlaxoSmithKline Biologicals S.A. The European Commission was notified by a letter dated 12 August 2011 of the MAH's decision to voluntarily withdraw the marketing authorisation as of the Commission Decision date for Prepandemic influenza vaccine (H5N1) GlaxoSmithKline Biologicals for commercial reasons. Prepandemic influenza vaccine (H5N1) GlaxoSmithKline Biologicals was not marketed in any country of the European Union.

On 3 October 2011 the European Commission issued a decision to withdraw the marketing authorisation for Prepandemic influenza vaccine (H5N1) GlaxoSmithKline Biologicals.

Pursuant to this decision the European Public Assessment Report for Prepandemic influenza vaccine (H5N1) GlaxoSmithKline Biologicals is updated to reflect that the marketing authorisation is no longer valid.

Prepandemic Influenza Vaccine (H5N1) (Split Virion, Inactivated, Adjuvanted) GlaxoSmithKline Biologicals : EPAR - Summary for the public

English (EN) (269.41 KB - PDF)

**First published:** 17/08/2009

**Last updated:** 21/03/2012

[View](/en/documents/overview/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-462)

български (BG) (502.77 KB - PDF)

**First published:**

17/08/2009

**Last updated:**

21/03/2012

[View](/bg/documents/overview/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-summary-public_bg.pdf)

español (ES) (274.84 KB - PDF)

**First published:**

17/08/2009

**Last updated:**

21/03/2012

[View](/es/documents/overview/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-summary-public_es.pdf)

čeština (CS) (450.72 KB - PDF)

**First published:**

17/08/2009

**Last updated:**

21/03/2012

[View](/cs/documents/overview/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-summary-public_cs.pdf)

dansk (DA) (271.24 KB - PDF)

**First published:**

17/08/2009

**Last updated:**

21/03/2012

[View](/da/documents/overview/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-summary-public_da.pdf)

Deutsch (DE) (276.48 KB - PDF)

**First published:**

17/08/2009

**Last updated:**

21/03/2012

[View](/de/documents/overview/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-summary-public_de.pdf)

eesti keel (ET) (270.14 KB - PDF)

**First published:**

17/08/2009

**Last updated:**

21/03/2012

[View](/et/documents/overview/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-summary-public_et.pdf)

ελληνικά (EL) (490.91 KB - PDF)

**First published:**

17/08/2009

**Last updated:**

21/03/2012

[View](/el/documents/overview/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-summary-public_el.pdf)

français (FR) (275.43 KB - PDF)

**First published:**

17/08/2009

**Last updated:**

21/03/2012

[View](/fr/documents/overview/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-summary-public_fr.pdf)

italiano (IT) (273.28 KB - PDF)

**First published:**

17/08/2009

**Last updated:**

21/03/2012

[View](/it/documents/overview/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-summary-public_it.pdf)

latviešu valoda (LV) (419.13 KB - PDF)

**First published:**

17/08/2009

**Last updated:**

21/03/2012

[View](/lv/documents/overview/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (394.32 KB - PDF)

**First published:**

17/08/2009

**Last updated:**

21/03/2012

[View](/lt/documents/overview/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-summary-public_lt.pdf)

magyar (HU) (415.34 KB - PDF)

**First published:**

17/08/2009

**Last updated:**

21/03/2012

[View](/hu/documents/overview/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-summary-public_hu.pdf)

Malti (MT) (456.06 KB - PDF)

**First published:**

17/08/2009

**Last updated:**

21/03/2012

[View](/mt/documents/overview/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-summary-public_mt.pdf)

Nederlands (NL) (273.25 KB - PDF)

**First published:**

17/08/2009

**Last updated:**

21/03/2012

[View](/nl/documents/overview/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-summary-public_nl.pdf)

polski (PL) (432.89 KB - PDF)

**First published:**

17/08/2009

**Last updated:**

21/03/2012

[View](/pl/documents/overview/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-summary-public_pl.pdf)

português (PT) (275.18 KB - PDF)

**First published:**

17/08/2009

**Last updated:**

21/03/2012

[View](/pt/documents/overview/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-summary-public_pt.pdf)

română (RO) (387.49 KB - PDF)

**First published:**

17/08/2009

**Last updated:**

21/03/2012

[View](/ro/documents/overview/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-summary-public_ro.pdf)

slovenčina (SK) (406.75 KB - PDF)

**First published:**

17/08/2009

**Last updated:**

21/03/2012

[View](/sk/documents/overview/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-summary-public_sk.pdf)

slovenščina (SL) (397.03 KB - PDF)

**First published:**

17/08/2009

**Last updated:**

21/03/2012

[View](/sl/documents/overview/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-summary-public_sl.pdf)

Suomi (FI) (271.22 KB - PDF)

**First published:**

17/08/2009

**Last updated:**

21/03/2012

[View](/fi/documents/overview/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-summary-public_fi.pdf)

svenska (SV) (270.87 KB - PDF)

**First published:**

17/08/2009

**Last updated:**

21/03/2012

[View](/sv/documents/overview/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-summary-public_sv.pdf)

## Product information

Prepandemic Influenza Vaccine (H5N1) (Split Virion, Inactivated, Adjuvanted) GlaxoSmithKline Biologicals : EPAR - Product Information

English (EN) (563.12 KB - PDF)

**First published:** 07/12/2009

**Last updated:** 21/03/2012

[View](/en/documents/product-information/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-product-information_en.pdf)

[Other languages (21)](#file-language-dropdown-902)

български (BG) (1.24 MB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/03/2012

[View](/bg/documents/product-information/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-product-information_bg.pdf)

español (ES) (575.79 KB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/03/2012

[View](/es/documents/product-information/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-product-information_es.pdf)

čeština (CS) (938.69 KB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/03/2012

[View](/cs/documents/product-information/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-product-information_cs.pdf)

dansk (DA) (576.31 KB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/03/2012

[View](/da/documents/product-information/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-product-information_da.pdf)

Deutsch (DE) (579.84 KB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/03/2012

[View](/de/documents/product-information/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-product-information_de.pdf)

eesti keel (ET) (562.88 KB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/03/2012

[View](/et/documents/product-information/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-product-information_et.pdf)

ελληνικά (EL) (1.31 MB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/03/2012

[View](/el/documents/product-information/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-product-information_el.pdf)

français (FR) (573.47 KB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/03/2012

[View](/fr/documents/product-information/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-product-information_fr.pdf)

italiano (IT) (577.51 KB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/03/2012

[View](/it/documents/product-information/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-product-information_it.pdf)

latviešu valoda (LV) (1009.3 KB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/03/2012

[View](/lv/documents/product-information/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-product-information_lv.pdf)

lietuvių kalba (LT) (649.07 KB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/03/2012

[View](/lt/documents/product-information/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-product-information_lt.pdf)

magyar (HU) (936.09 KB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/03/2012

[View](/hu/documents/product-information/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-product-information_hu.pdf)

Malti (MT) (978.27 KB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/03/2012

[View](/mt/documents/product-information/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-product-information_mt.pdf)

Nederlands (NL) (579.38 KB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/03/2012

[View](/nl/documents/product-information/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-product-information_nl.pdf)

polski (PL) (999.51 KB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/03/2012

[View](/pl/documents/product-information/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-product-information_pl.pdf)

português (PT) (581.21 KB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/03/2012

[View](/pt/documents/product-information/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-product-information_pt.pdf)

română (RO) (656.4 KB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/03/2012

[View](/ro/documents/product-information/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-product-information_ro.pdf)

slovenčina (SK) (957.88 KB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/03/2012

[View](/sk/documents/product-information/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-product-information_sk.pdf)

slovenščina (SL) (908.17 KB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/03/2012

[View](/sl/documents/product-information/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-product-information_sl.pdf)

Suomi (FI) (568.38 KB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/03/2012

[View](/fi/documents/product-information/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-product-information_fi.pdf)

svenska (SV) (567.92 KB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/03/2012

[View](/sv/documents/product-information/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0013 03/10/2011

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Prepandemic Influenza Vaccine (H5N1) (Split Virion, Inactivated, Adjuvanted) GlaxoSmithKline Biologicals : EPAR - All Authorised presentations

English (EN) (240.13 KB - PDF)

**First published:** 23/10/2008

**Last updated:** 21/03/2012

[View](/en/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-all-authorised-presentations_en.pdf)

[Other languages (21)](#file-language-dropdown-942)

български (BG) (333.25 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

21/03/2012

[View](/bg/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-all-authorised-presentations_bg.pdf)

español (ES) (237.14 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

21/03/2012

[View](/es/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-all-authorised-presentations_es.pdf)

čeština (CS) (320.99 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

21/03/2012

[View](/cs/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (240.64 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

21/03/2012

[View](/da/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (240.59 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

21/03/2012

[View](/de/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (240.71 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

21/03/2012

[View](/et/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (325.39 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

21/03/2012

[View](/el/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-all-authorised-presentations_el.pdf)

français (FR) (240.53 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

21/03/2012

[View](/fr/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-all-authorised-presentations_fr.pdf)

italiano (IT) (240.19 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

21/03/2012

[View](/it/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (319.39 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

21/03/2012

[View](/lv/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (310.55 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

21/03/2012

[View](/lt/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (279.39 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

21/03/2012

[View](/hu/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (322.69 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

21/03/2012

[View](/mt/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (240.19 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

21/03/2012

[View](/nl/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-all-authorised-presentations_nl.pdf)

polski (PL) (324.58 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

21/03/2012

[View](/pl/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-all-authorised-presentations_pl.pdf)

português (PT) (240.64 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

21/03/2012

[View](/pt/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-all-authorised-presentations_pt.pdf)

română (RO) (309.23 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

21/03/2012

[View](/ro/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (319.53 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

21/03/2012

[View](/sk/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (288.58 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

21/03/2012

[View](/sl/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (240.37 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

21/03/2012

[View](/fi/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (240.73 KB - PDF)

**First published:**

23/10/2008

**Last updated:**

21/03/2012

[View](/sv/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Prepandemic Influenza Vaccine (H5N1) (Split Virion, Inactivated, Adjuvanted) GlaxoSmithKline Biologicals Active substance split influenza virus, inactivated, containing antigen: A/VietNam/1194/2004 (H5N1) like strain used (NIBRG-14) International non-proprietary name (INN) or common name prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) Therapeutic area (MeSH)

- Influenza, Human
- Immunization
- Disease Outbreaks

Anatomical therapeutic chemical (ATC) code J07BB02

### Pharmacotherapeutic group

Vaccines

### Therapeutic indication

Active immunisation against H5N1 subtype of Influenza A virus.

This indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of vaccine prepared from A/VietNam/1194/2004 NIBRG-14 (H5N1) (see section 5.1).

Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals 3.75 µg should be used in accordance with official guidance.

## Authorisation details

EMA product number EMEA/H/C/001015 Marketing authorisation holder

GlaxoSmithKline Biologicals S.A.

Rue de l'Institut, 89

Marketing authorisation issued 26/09/2008 Withdrawal of marketing authorisation 03/11/2011 Revision 3

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Prepandemic Influenza Vaccine (H5N1) (Split Virion, Inactivated, Adjuvanted) GlaxoSmithKline Biologicals : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (306.14 KB - PDF)

**First published:** 07/12/2009

**Last updated:** 21/03/2012

[View](/en/documents/procedural-steps-after/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Prepandemic Influenza Vaccine (H5N1) (Split Virion, Inactivated, Adjuvanted) GlaxoSmithKline Biologicals-H-C-1051-II-01 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMEA/CHMP/352156/2009

English (EN) (679.34 KB - PDF)

**First published:** 17/08/2009

**Last updated:** 21/03/2012

[View](/en/documents/variation-report/prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals-h-c-1051-ii-01-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals

Adopted

Reference Number: EMEA/CHMP/332974/2009

English (EN) (32.94 KB - PDF)

**First published:** 29/05/2009

**Last updated:** 29/05/2009

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals_en.pdf)

## Initial marketing authorisation documents

Committee for medicinal products for human use, summary of positive opinion for Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals

Reference Number: EMEA/CHMP/366446/2008

English (EN) (33.23 KB - PDF)

**First published:** 24/07/2008

**Last updated:** 24/07/2008

[View](/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-prepandemic-influenza-vaccine-h5n1-split-virion-inactivated-adjuvanted-glaxosmithkline-biologicals_en.pdf)

**This page was last updated on** 21/03/2012

## Share this page

[Back to top](#main-content)